van Vugt MATM - Search Results

1

Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities.

de Vries G, Rosas-Plaza X, van Vugt MATM, Gietema JA, de Jong S. de Vries G, et al. Among authors: van vugt matm. Cancer Treat Rev. 2020 Aug;88:102054. doi: 10.1016/j.ctrv.2020.102054. Epub 2020 Jun 8. Cancer Treat Rev. 2020. PMID: 32593915 Free article. Review.

2

Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome.

Heijink DM, de Vries EG, Koornstra JJ, Hospers GA, Hofstra RM, van Vugt MA, de Jong S, Kleibeuker JH. Heijink DM, et al. Crit Rev Oncol Hematol. 2011 Nov;80(2):264-77. doi: 10.1016/j.critrevonc.2010.11.009. Epub 2010 Dec 14. Crit Rev Oncol Hematol. 2011. PMID: 21159521 Review.

3

The role of ATM and 53BP1 as predictive markers in cervical cancer.

Roossink F, Wieringa HW, Noordhuis MG, ten Hoor KA, Kok M, Slagter-Menkema L, Hollema H, de Bock GH, Pras E, de Vries EG, de Jong S, van der Zee AG, Schuuring E, Wisman GB, van Vugt MA. Roossink F, et al. Int J Cancer. 2012 Nov 1;131(9):2056-66. doi: 10.1002/ijc.27488. Epub 2012 Mar 29. Int J Cancer. 2012. PMID: 22323184 Free PMC article.

4

Toward molecular imaging-driven drug development in oncology.

de Vries EG, Oude Munnink TH, van Vugt MA, Nagengast WB. de Vries EG, et al. Cancer Discov. 2011 Jun;1(1):25-8. doi: 10.1158/2159-8274.CD-11-0051. Epub 2011 Jun 1. Cancer Discov. 2011. PMID: 22586317

5

Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer.

Koster R, van Vugt MA, Timmer-Bosscha H, Gietema JA, de Jong S. Koster R, et al. Expert Rev Mol Med. 2013 Sep 30;15:e12. doi: 10.1017/erm.2013.13. Expert Rev Mol Med. 2013. PMID: 24074238 Review.

6

Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.

Alkema NG, Tomar T, van der Zee AG, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA, Wisman GB. Alkema NG, et al. Gynecol Oncol. 2014 Jun;133(3):591-8. doi: 10.1016/j.ygyno.2014.03.557. Epub 2014 Mar 20. Gynecol Oncol. 2014. PMID: 24657486

7

Rectal and colon cancer: Not just a different anatomic site.

Tamas K, Walenkamp AM, de Vries EG, van Vugt MA, Beets-Tan RG, van Etten B, de Groot DJ, Hospers GA. Tamas K, et al. Cancer Treat Rev. 2015 Sep;41(8):671-9. doi: 10.1016/j.ctrv.2015.06.007. Epub 2015 Jun 28. Cancer Treat Rev. 2015. PMID: 26145760 Review.

8

Breaking the DNA damage response to improve cervical cancer treatment.

Wieringa HW, van der Zee AG, de Vries EG, van Vugt MA. Wieringa HW, et al. Cancer Treat Rev. 2016 Jan;42:30-40. doi: 10.1016/j.ctrv.2015.11.008. Epub 2015 Nov 24. Cancer Treat Rev. 2016. PMID: 26643553 Review.

9

Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.

Alkema NG, Wisman GB, van der Zee AG, van Vugt MA, de Jong S. Alkema NG, et al. Drug Resist Updat. 2016 Jan;24:55-69. doi: 10.1016/j.drup.2015.11.005. Epub 2015 Nov 26. Drug Resist Updat. 2016. PMID: 26830315 Review.

10

Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.

Fedoseienko A, Wieringa HW, Wisman GB, Duiker E, Reyners AK, Hofker MH, van der Zee AG, van de Sluis B, van Vugt MA. Fedoseienko A, et al. PLoS One. 2016 Oct 27;11(10):e0165385. doi: 10.1371/journal.pone.0165385. eCollection 2016. PLoS One. 2016. PMID: 27788210 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

102 results

Search Page